Scientific Program
| Thursday, October 19 |
|
| Hall B | |
| 17:15-17:45 | ECP Delphi Panel – Understanding the evolving practices of prescribing ECP in the real world Industry-supported Meet the Expert Session |
| 17:45-18:00 | Technical Break |
| 18:00-18:30 | CMV Management post HSCT Industry-supported Meet the Expert Session |
| Friday, October 20 |
||
| Hall A | ||
| 08:00-08:30 | Good Morning Coffee | |
| 08:30-09:30 | Cell Therapy Today: Scientific evolution of T-Cell Approaches Industry-supported Pre-Congress Workshop |
|
| 09:30-09:40 | Short Break | |
| 09:40-09:45 | Welcome Note: Nicolaus Kröger, Germany and Arnon Nagler, Israel | |
| 09:45-11:05 | Opening Session: BiTE vs CAR-T | |
| 09:45-10:15 | Controversy: BiTE vs CAR-T in relapsed/refratory multiple myeloma (MM) Moderator: Arnon Nagler, Israel |
|
| 09:45-10:00 | Pro BiTE: Evangelos Terpos, Greece | |
| 10:00-10:15 | Pro CAR-T: Nikhil Munshi, USA | |
| 10:15-10:45 | Controversy: BiTE vs CAR-T in DLBCL Moderator: Nicolaus Kröger, Germany |
|
| 10:15-10:30 | Pro BiTE: Carmelo Carlo-Stella, Italy | |
| 10:30-10:45 | Pro CAR-T: Michael Bishop, USA | |
| 10:45-11:05 | Panel discussion: All session faculty |
|
| 11:05-11:25 | Coffee Break, Poster Viewing and Visit Exhibition | |
| Hall A | Hall B | |
| 11:25-12:45 | Session 1: AML | Session 2: MDS |
| 11:25-11:55 | Controversy: Do we need MRD negativity pre-allo HSCT in AML? Moderator: Charles Craddock, UK |
Controversy: Should we perform a transplant in MDS patients with p53? Moderator: Alessandro Rambaldi, Italy |
| 11:25-11:40 | Yes: Roland Walter, USA | Yes: Bart Lee Scott, USA |
| 11:40-11:55 | No: Michael Heuser, Germany | No: Magnus Tobiasson, Sweden |
| 11:55-12:25 | Controversy: Is there a role for salvage therapy pre-allo HSCT in refractory/relapsed AML? Moderator: Arnon Nagler, Israel |
Controversy: Are there patients with low IPSSR who benefit from early transplant? Moderator: Alessandro Rambaldi, Italy |
| 11:55-12:10 | Yes: Charles Craddock, UK | Yes: Ibrahim Yakoub-Agha, France |
| 12:10-12:25 | No: Johannes Schetelig, Germany | No: Matteo Della Porta, Italy |
| 12:25-12:45 | Panel discussion: All session faculty | Panel discussion: All session faculty |
| 12:45-13:30 | Lunch Pick-up, Poster Viewing and Visit Exhibition | |
| 13:30-14:30 | Clinical outcomes in acute leukemias – a case-based approach Industry-supported Lunch Symposium (Hall A) |
|
| 14:30-14:45 | Short Break | |
| Hall A | Hall B | |
| 14:45-16:15 | Session 3: Allogeneic transplantation | Session 4: Lymphoma |
| 14:45-15:15 | Controversy: Is treosulfan conditioning the new standard for allogeneic SCT in MDS? Moderator: Bart Lee Scott, USA |
Controversy: Is there still a role for auto transplant in MCL? Moderator: Arnon Nagler, Israel |
| 14:45-15:00 | Yes: Avichai Shimoni, Israel | 14:45-15:00 – Yes: Ali Bazarbachi, Lebanon |
| 15:00-15:15 | No: Alessandro Rambaldi, Italy | 15:00-15:15 – No: Georg Hess, Germany
15:15-15:30 – Discussion |
| 15:15-15:45 | Controversy: Are venetoclax combinations replacing anthracycline/araC containing induction regimen prior to allogeneic stem cell transplantation? Moderator: Michael Heuser, Germany |
Controversy: Is there is still a role for allo transplant in Hodgkin lymphoma? Moderator: Arnon Nagler, Israel |
| 15:15-15:30 | Yes: Claudio Cerchione, Italy | 15:30-15:45 – Yes: Ali Bazarbachi, Lebanon |
| 15:30-15:45 | No: Lars Bullinger, Germany | 15:45-16:00 – No: Nicolaus Kröger, Germany |
| 15:45-16:15 | Panel discussion: All session faculty | 16:00-16:15 – Discussion |
| 16:15-16:45 | Coffee Break, Poster Viewing and Visit Exhibition | |
| Hall A | Hall B | |
| 16:45-18:15 | Session 5: GvHD | Session 6: MPN |
| 16:45-17:15 | Controversy: Is PTCy/MMF/CNI or ATG/MMF/CNI the standard of care GvHD prophylaxis in MUD? Moderator: Corey Cutler, USA |
Controversy: Should patients be monitored post allo with molecular markers? Moderator: Rachel Salit, USA |
| 16:45-17:00 | PTCy: Leonido Luznik, USA | Yes: Nicolaus Kröger, Germany |
| 17:00-17:15 | ATG: Francesca Bonifazi, Italy | No: Andrea Bacigalupo, Italy |
| 17:15-17:45 | Controversy: Are JAK inhibitors the new standard for all SR-acute and chronic GvHD manifestations? Moderator: Leonido Luznik, USA |
Controversy: Should KRAS or others be added to ASXL1, SRSF2 and EZH2 as bad predictors indicating transplants in myelofibrosis? Moderator: Andrea Bacigalupo, Italy |
| 17:15-17:30 | Yes: Robert Zeiser, Germany | Yes: Nico Gagelmann, Germany |
| 17:30-17:45 | No: Corey Cutler, USA | No: Rachel Salit, USA |
| 17:45-18:15 | Panel discussion: All session faculty | Panel discussion: All session faculty |
| 18:15-19:15 | Poster Walk and Awards Session (Poster Area) |
|
| Saturday, October 21 |
||
| Hall A | Hall B | |
| 09:15-10:45 | Session 7: Donor selection | Session 8: Haploidentical transplants |
| 09:15-09:45 | Controversy: Is selecting according to HLA including HLA B leader and permissive MM for allogeneic transplants in the era of PTCy still needed? Moderator: Robert Soiffer, USA |
Controversy: Does PTCy increase late relapses and late infections post haploidentical transplants? Moderator: Bart Lee Scott, USA |
| 09:15-09:30 | Yes: Katharina Fleischhauer, Germany | Yes: Olaf Penack, Germany |
| 09:30-09:45 | No: Bronwen Shaw, USA | No: Christopher Kanakry, USA |
| 09:45-10:15 | Controversy: Is younger MUD better than HLA-sibling in older MDS and AML patients? Moderator: Bronwen Shaw, USA |
Controversy: Does PTCy in haplo transplant for children replace ex vivo T-cell depletion? Moderator: Christopher Kanakry, USA |
| 09:45-10:00 | Yes: Wael Saber, USA | Yes: Michael Pulsipher, USA |
| 10:00-10:15 | No: Robert Soiffer, USA | No: Peter Bader, Germany |
| 10:15-10:45 | Panel discussion: All session faculty | Panel discussion: All session faculty |
| 10:45-11:15 | Coffee Break, Poster Viewing and Visit Exhibition | |
| Hall A | Hall B | |
| 11:15-12:45 | Session 9: Immunotherapy I | Session 10: ALL |
| 11:15-11:45 | Controversy: Did we progress with CAR-T in AML? Moderator: Stephan Mielke, Sweden |
Controversy: Are we ready to abandon allo in ALL? Moderator: Nicola Gökbuget, Germany |
| 11:15-11:30 | Yes: Saar Gill, USA | Yes: Nicholas Short, USA |
| 11:30-11:45 | No: Marion Subklewe, Germany | No: Arnon Nagler, Israel |
| 11:45-12:15 | Controversy: TCR editing vs CAR in malignancies Moderator: Marion Subklewe, Germany |
Controversy: Do we need allo post CAR in ALL? Moderator: Ibrahim Yakoub-Agha, France |
| 11:45-12:00 | Pro TCR: Chiara Bonini, Italy | Yes: Peihua Lu, China |
| 12:00-12:15 | Pro CAR: Stephan Mielke, Sweden | No: Nicola Gökbuget, Germany |
| 12:15-12:45 | Panel discussion: All session faculty | Panel discussion: All session faculty |
| 12:45-13:30 | Lunch Pick-up, Poster Viewing and Visit Exhibition | |
| 13:30-15:00 | CMV-Management: Up to date Management of CMV in HSCT and CAR-T Industry-supported Lunch Symposium (Hall A) |
|
| 15:00-15:15 | Short Break | |
| Hall A | Hall B | |
| 15:15-16:45 | Session 11: Immunotherapy II | Session 12: Pediatrics and non-malignancies |
| 15:15-15:45 | Controversy: Are CAR-T cells replacing autologous SCT in autoimmune disease? Moderator: Nicolaus Kröger, Germany |
Controversy: SCT vs gene therapy in sickle cell anemia and thalassemia Moderator: Selim Corbacioglu, Germany |
| 15:15-15:30 | Yes: Dominique Farge, France | 15:15-15:30 – SCT: Suradej Hongeng, Thailand |
| 15:30-15:45 | No: Riccardo Saccardi, Italy | 15:30-15:45 – Gene therapy: Markus Mapara, USA |
| 15:45-16:00 – Discussion | ||
| 15:45-16:15 | Controversy: Is point-of-care production of CAR-T cells the favorable way to go forward? Moderator: Claudio Cerchione, Italy |
Controversy: Allogeneic/Gene-therapy for autoimmune disease Moderator: Peter Bader, Germany |
| 15:45-16:00 | Yes: Stephan Mielke, Sweden | 16:00-16:15 – Yes: Selim Corbacioglu, Germany |
| 16:00-16:15 | No: Christian Chabannon, France | 16:15-16:30 – No: Tobias Alexander, Germany |
| 16:30-16:45 – Discussion | ||
| 16:15-16:45 | Panel discussion: All session faculty | |
| 16:45 | Closing Remarks: Nicolaus Kröger, Germany and Arnon Nagler, Israel (Hall A) |
|